TrialBlood cancer journal2021

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.

Joseph Mikhael et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.